Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Net Cash Flow of $457.4 million for Q1 2026, up 453.08% year-over-year from $82.7 million in Q1 2025, and up 244.69% quarter-over-quarter from $132.7 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at $457.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 453.08% year-over-year to $457.4 million; the TTM figure through Mar 2026 stood at $799.4 million (up 117.81% YoY), while the FY2025 annual figure was $424.7 million, up 107.38% from the prior year.
- Net Cash Flow for Q1 2026 stood at $457.4 million, up from $132.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $1.3 billion in Q4 2022, with the low at -$4.6 billion in Q2 2024.
- The 5-year median for Net Cash Flow is $239.4 million (2025), against an average of -$76.5 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow surged 558.1% in 2022, then sank 639.74% in 2024.
- Vertex Pharmaceuticals' Net Cash Flow stood at $1.3 billion in 2022, then slumped by 159.63% to -$771.7 million in 2023, then advanced by 18.54% to -$628.6 million in 2024, then surged by 121.11% to $132.7 million in 2025, then soared by 244.69% to $457.4 million in 2026.
- Business Quant data shows VRTX's Net Cash Flow at $457.4 million in Q1 2026, $132.7 million in Q4 2025, and -$30.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 652.90 Mn |
| Jun 30, 2026 | 652.90 Mn |
| Mar 31, 2026 | 457.40 Mn |
| Mar 31, 2026 | 457.40 Mn |
| Dec 31, 2025 | 132.70 Mn |
| Dec 31, 2025 | 132.70 Mn |
| Sep 30, 2025 | -30.10 Mn |
| Sep 30, 2025 | -30.10 Mn |
| Jun 30, 2025 | 239.40 Mn |
| Jun 30, 2025 | 239.40 Mn |
| Mar 31, 2025 | 82.70 Mn |
| Mar 31, 2025 | 82.70 Mn |
| Dec 31, 2024 | -628.60 Mn |
| Dec 31, 2024 | -628.60 Mn |
| Sep 30, 2024 | 634.30 Mn |
| Sep 30, 2024 | 634.30 Mn |
| Jun 30, 2024 | -4.58 Bn |
| Jun 30, 2024 | -4.58 Bn |
| Mar 31, 2024 | -1.19 Bn |
| Mar 31, 2024 | -1.19 Bn |